|
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Orally active and blood-brain barrier-permeable specific inhibitors for cathepsin B can be potentially effective new pharmaceutical interventions against inflammatory brain diseases and brain aging.
|
31535638 |
2020 |
|
Lupus Erythematosus, Systemic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Genetic variants in BLK gene might affect SLE by influencing BLK gene expression and plasma cathepsin B protein level.
|
31670388 |
2020 |
|
Aspergillosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using this method to select from synthetic human antibody libraries, we isolated panels of mAbs inhibiting 5 targets of 4 main protease classes: matrix metalloproteinases (MMP-14, a predominant target in metastasis; MMP-9, in neuropathic pain), β-secretase 1 (BACE-1, an aspartic protease in Alzheimer's disease), cathepsin B (a cysteine protease in cancer), and Alp2 (a serine protease in aspergillosis).
|
31363054 |
2019 |
|
Autistic Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cathepsin B inhibition ameliorates leukocyte-endothelial adhesion in the BTBR mouse model of autism.
|
30328295 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cathepsin B defines leader cells during the collective invasion of salivary adenoid cystic carcinoma.
|
30968153 |
2019 |
|
Demyelinating Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Data indicate cathepsin B as a key molecule mediating neurodegeneration, opening research pathways for therapeutic targeting of LSDs and other demyelinating diseases.
|
30530526 |
2019 |
|
Contact Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, topically applied cathepsin B inhibitors might effectively limit DTHR such as contact dermatitis or psoriasis.
|
31281521 |
2019 |
|
Epilepsy, Temporal Lobe
|
0.010 |
Biomarker
|
disease |
BEFREE |
High levels of C-reactive protein (TLE = 1.4 ± 0.3 µg/mL), PKal (TLE = 5.4 ± 0.4 U/mL), and CatB (TLE = 4.9 ± 0.4 U/mL) were also evident in the serum of TLE patients comparing to controls.
|
31206169 |
2019 |
|
Giardiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the secreted Giardia CPs are key players in the interaction with host cells during Giardia infections since they can cleave several components of the human mucosal defense machinery.
|
30458129 |
2019 |
|
Keloid
|
0.010 |
Biomarker
|
disease |
BEFREE |
We hypothesized that cathepsin B (cathB), cathepsin D (cathD) and cathepsin G (cathG) are present within the ESC-like population in KLs and contribute to bypass loops of the RAS.
|
31524804 |
2019 |
|
Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Total renal volume, cortical volume, and urinary activity of N-acetyl-β-D-glucosaminidase and cathepsin B may be suggested as indicators for the early recognition of GDM neonates at long-term risk of hypertension and kidney disease.
|
30925803 |
2019 |
|
Lymphohistiocytosis, Hemophagocytic
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b> ACTB: actin, beta; CTSB: cathepsin B; EEA1: early endosome antigen 1; ESCRT: endosomal sorting complex required for transport; FHL3: familial hemophagocytic; lymphohistiocytosis type 3; HEX: hexosaminidase; HLH: hemophagocytic lymphohistiocytosis; LSD: lysosomal storage disorder; MEF: mouse embryonic fibroblast; SEM: standard errors of the mean; SNARE: soluble n-ethylmaleimide-sensitive-factor attachment receptor; STX: syntaxin; SYT7: synaptotagmin VII; TFE3: transcription factor E3; TFEB: transcription factor EB; TIRF: total internal reflection fluorescence ULK1: unc-51 like kinase 1; UNC13D: unc-13 homolog d; VAMP: vesicle-associate membrane protein; WT: wild-type.
|
30892133 |
2019 |
|
Nephrotic Syndrome
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome.
|
31368174 |
2019 |
|
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Our studies demonstrate that SAA increases the cytokine interleukin-1β (IL-1β), which is mediated by Nod-like receptor protein 3 (NLRP3) inflammasome, cathepsin B, and caspase-1 and may play a role in the pathogenesis of neurological disorders.
|
31611307 |
2019 |
|
Neuralgia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Using this method to select from synthetic human antibody libraries, we isolated panels of mAbs inhibiting 5 targets of 4 main protease classes: matrix metalloproteinases (MMP-14, a predominant target in metastasis; MMP-9, in neuropathic pain), β-secretase 1 (BACE-1, an aspartic protease in Alzheimer's disease), cathepsin B (a cysteine protease in cancer), and Alp2 (a serine protease in aspergillosis).
|
31363054 |
2019 |
|
Osteitis Deformans
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abbreviations: AAA: ATPases Associated with diverse cellular Activities; TUBA1A/α-tubulin: tubulin alpha 1a; ATG5: autophagy related 5; ATG7: autophagy related 7; ACTA1: actin alpha 1, skeletal muscle; CLEAR: coordinated lysosomal expression and regulation; CTSB/D: cathepsin B/D; Ctrl: control; DAPI: diamidino-2-phenylindole; EBSS: Earle's balanced salt solution; ELDR: endolysosomal damage response; ESCRT: endosomal sorting complexes required for transport; Gastroc/G: gastrocnemius; H&E: hematoxylin and eosin; HSPA5/GRP78: heat shock protein family A (Hsp70) member 5; IBMPFD/ALS: inclusion body myopathy associated with Paget disease of the bone, frontotemporal dementia and amyotrophic lateral sclerosis; i.p.
|
30654731 |
2019 |
|
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, topically applied cathepsin B inhibitors might effectively limit DTHR such as contact dermatitis or psoriasis.
|
31281521 |
2019 |
|
Seizures
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Human hippocampal sclerotic tissues removed after surgery for seizure control, plasma, and serum were used in the following assays: immunostaining for white blood cells in the TLE hippocampus, C-reactive protein in serum, quantification of plasma kallikrein (PKal) and cathepsin B (CatB) activity in serum and plasma, quantification of C1-inhibitor, analysis of high-molecular-weight kininogen (H-kininogen) fragments, and activation of plasma prekallikrein for comparison with healthy controls.
|
31206169 |
2019 |
|
Gestational Diabetes
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Total renal volume, cortical volume, and urinary activity of N-acetyl-β-D-glucosaminidase and cathepsin B may be suggested as indicators for the early recognition of GDM neonates at long-term risk of hypertension and kidney disease.
|
30925803 |
2019 |
|
Adenocarcinoma of rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
It appears that the pericellular localization of cathepsin B, also observed in colon and rectum adenocarcinoma tissue samples, plays a key role in its function.
|
30818851 |
2019 |
|
Alkalemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, CTSB-mediated activation of the K24G mutant became more sensitive to inhibition by increasing pH.
|
31235832 |
2019 |
|
Gallbladder Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> Activities of CTSL and CTSB were assayed in the gallbladder (GB) tissues obtained from GBC patients (<i>n</i> = 43) and control subjects (<i>n</i> = 69).
|
31824841 |
2019 |
|
Cerebral atrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
CID administration attenuates brain atrophy and improves neurologic deficits and inhibits astrogliosis and glial scar formation after ischemic stroke via reducing the activation and release of cathepsin B from the lysosome into the cytoplasm.
|
30315251 |
2019 |
|
Adenocarcinoma of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cathepsin B Is Upregulated and Mediates ECM Degradation in Colon Adenocarcinoma HT29 Cells Overexpressing Snail.
|
30818851 |
2019 |
|
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, intralateral ventricle injection of LLOMe-treated CatB-overexpressing microglia induced cognitive impairment in middle-aged mice.
|
30575263 |
2019 |